IFRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
InflaRx NV (IFRX) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock shows some positive signs such as hedge fund interest and a bullish analyst rating, the technical indicators suggest the stock is overbought, and the financial performance remains weak. Additionally, there are no significant news catalysts or recent congress trading data to support a strong buy decision.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI of 81.133 suggests the stock is overbought. Moving averages are converging, and the price is near a resistance level of 1.2, with limited upside potential in the short term.
Hedge funds are significantly increasing their positions in the stock, with a 425.33% increase in buying activity over the last quarter. Analysts maintain a Buy rating and see the stock as undervalued, with a price target of $14.
The stock is overbought based on RSI, and there are no recent news events or congress trading data to act as a catalyst. Financial performance remains weak, with negative net income and EPS.
In Q4 2025, revenue remained at 0 with no growth. Net income improved YoY but remains negative at -10,642,392. EPS improved to -0.15, up 66.67% YoY, and gross margin improved significantly but remains negative.
Guggenheim analyst lowered the price target from $22 to $14 but maintained a Buy rating, citing the stock as undervalued and highlighting potential value in ANCA-associated vasculitis.
